# RCUS — Arcus Biosciences Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** RCUS  
**Sources:** 25  
**Published:** 2026-10-26  
**Canonical:** https://app.k3vl4r.com/research/deep-research-rcus-arcus-biosciences-inc-catalysts-narrative-risks-9350

---

# Arcus Biosciences (NYSE: RCUS) — Research Snapshot as of 2026-10-26

**Company profile.** Arcus Biosciences is a (largely "late") clinical-stage biopharmaceutical company headquartered in Hayward, California, developing cancer and immune-disease therapies. It trades on the NYSE under ticker RCUS (ISIN US03969F1093). [[1]](https://www.ad-hoc-news.de/boerse/news/nebenwerte/jpmorgan-starts-coverage-of-arcus-biosciences-stock-at-overweight/70334421) [[20]](https://arcusbio.com/) [[23]](https://stockanalysis.com/stocks/rcus/) [[25]](https://www.morningstar.com/stocks/xnys/rcus/quote) As of late October 2026 the stock trades near ~$18.5–19.4 with a market capitalization of roughly ~$2.33B–$2.63B depending on the share count used. [[12]](https://www.marketbeat.com/earnings/reports/2026-11-4-arcus-biosciences-inc-stock/) [[22]](https://finance.yahoo.com/quote/RCUS/) [[23]](https://stockanalysis.com/stocks/rcus/) [[25]](https://www.morningstar.com/stocks/xnys/rcus/quote)

## Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-rcus-arcus-biosciences-inc-catalysts-narrative-risks-9350 (free to sign up)._